Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker C, Gillessen Sommer S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5:v69-77.
22.07.2015Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
22.07.2015Ann Oncol 2015; 26 Suppl 5:v69-77
Parker C, Gillessen Sommer Silke, Heidenreich A, Horwich A, ESMO Guidelines Committee
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
Bachmann H, Aminossadati B, Schmalfeldt B, Burges A, Hillemanns P, Huober J, Wollschlaeger K, Sehouli J, Siffert W, Kuhlmann J, Kimmig R, du Bois A, Meier W, Wimberger P. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. Br J Clin Pharmacol 2015; 80:1139-48.
22.07.2015The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
22.07.2015Br J Clin Pharmacol 2015; 80:1139-48
Bachmann Hagen Sjard, Aminossadati Behnaz, Schmalfeldt Barbara, Burges Alexander, Hillemanns Peter, Huober Jens, Wollschlaeger Kerstin, Sehouli Jalid, Siffert Winfried, Kuhlmann Jan Dominik, Kimmig Rainer, du Bois Andreas, Meier Werner, Wimberger Pauline
Using lung cancer mortality to indirectly approximate smoking patterns in space
Jürgens V, ess s, Schwenkglenks M, Cerny T, Vounatsou P. Using lung cancer mortality to indirectly approximate smoking patterns in space. Spat Spatiotemporal Epidemiol 2015; 14-15:23-31.
13.07.2015Using lung cancer mortality to indirectly approximate smoking patterns in space
13.07.2015Spat Spatiotemporal Epidemiol 2015; 14-15:23-31
Jürgens Verena, ess silvia, Schwenkglenks Matthias, Cerny Thomas, Vounatsou Penelope
Primum non nocere
Templeton A, Šeruga B. Primum non nocere. Ann Oncol 2015; 26:2197-8.
13.07.2015Primum non nocere
13.07.2015Ann Oncol 2015; 26:2197-8
Templeton Arnoud, Šeruga B
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015; 33:2523-9.
06.07.2015Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
06.07.2015J Clin Oncol 2015; 33:2523-9
Mamot Christoph, Zucca Emanuele, Dirnhofer Stephan, Rusterholz Corinne, Biaggi Christine, Samarin Andrei, Hany Thomas, Gigli Federica, Krasniqi Fatime, Bargetzi Mario, Pless Miklos, Mey Ulrich, Driessen Christoph, Pabst Thomas, Renner Christoph, Hitz Felicitas, Klingbiel Dirk, Martinelli Giovanni
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137:2981-8.
06.07.2015Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
06.07.2015Int J Cancer 2015; 137:2981-8
Hein Alexander, Ekici Arif B, Hanusch Claus, Huober Jens, Liedtke Cornelia, Mau Christine, Moisse Matthieu, Müller Volkmar, Nekljudova Valentina, Peuteman Gilian, Rack Brigitte, Rübner Matthias, Van Brussel Thomas, Wang Liewei, Weinshilboum Richard M, Loibl Sibylle, Beckmann Matthias W, Kunz Georg, Lambrechts Diether, von Minckwitz Gunter, Häberle Lothar, Eidtmann Holger, Tesch Hans, Untch Michael, Hilfrich Jörn, Schem Christian, Rezai Mahdi, Gerber Bernd, Dan Costa Serban, Blohmer Jens-Uwe, Schwedler Kathrin, Kittel Kornelia, Fehm Tanja, Fasching Peter A
Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis
Marsico J, Rodriguez R, Müller J, Jörger M. Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis. J Cancer Res Ther 2015; 11:647.
01.07.2015Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis
01.07.2015J Cancer Res Ther 2015; 11:647
Marsico Jennifer Gibbons, Rodriguez Regulo, Müller Joachim, Jörger Markus
Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage.
Sigle J, Holbro A, Lehmann T, Infanti L, Gerull S, Stern M, Tichelli A, Passweg J, Buser A. Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage. Am J Clin Pathol 2015; 144:145-50.
01.07.2015Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage.
01.07.2015Am J Clin Pathol 2015; 144:145-50
Sigle Joerg P, Holbro Andreas, Lehmann Thomas, Infanti Laura, Gerull Sabine, Stern Martin, Tichelli André, Passweg Jakob, Buser Andreas
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer 2015; 121:3639-48.
25.06.2015A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
25.06.2015Cancer 2015; 121:3639-48
von Minckwitz Gunter, Thomssen Christoph, Huober Jens, Denkert Carsten, Alfer Joachim, Jackisch Christian, Nekljudova Valentina, Burchardi Nicole, Loibl Sibylle, Simon Eike, Stickeler Elmar, Potenberg Jochem, Conrad Bettina, Reimer Toralf, Decker Thomas, Eidtmann Holger, Eiermann Wolfgang, Hackmann John, Möbus Volker, Marme Frederik, German Breast Group Investigators
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
Loibl S, Mehta K, Nekljudova V, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Kümmel S, Paepke S, Untch M, Lederer B, Jackisch C, von Minckwitz G. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat 2015; 152:377-87.
25.06.2015Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
25.06.2015Breast Cancer Res Treat 2015; 152:377-87
Loibl Sibylle, Mehta Keyur, Nekljudova Valentina, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hanusch Claus, Hilfrich Jörn, Huober Jens, Schneeweiss Andreas, Kümmel Sherko, Paepke Stefan, Untch Michael, Lederer Bianca, Jackisch Christian, von Minckwitz Gunter
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol 2015; 76:383-96.
23.06.2015The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
23.06.2015Cancer Chemother Pharmacol 2015; 76:383-96
Kraus Johannes, Kraus Marianne, Liu Nora, Besse Lenka, Bader Jürgen, Geurink Paul P, de Bruin Gerjan, Kisselev Alexei F, Overkleeft Herman, Driessen Christoph
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Jackisch C, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Loibl S, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel) 2015; 10:211-9.
23.06.201514th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
23.06.2015Breast Care (Basel) 2015; 10:211-9
Jackisch Christian, Blohmer Jens-Uwe, Costa Serban-Dan, Decker Thomas, Diel Ingo, Fasching Peter A, Fehm Tanja, Janni Wolfgang, Lück Hans-Joachim, Maass Nicolai, Scharl Anton, Beckmann Matthias W, Loibl Sibylle, Thomssen Christoph, Harbeck Nadia, Huober Jens, von Minckwitz Gunter, Gerber Bernd, Kreipe Hans-Heinrich, Liedtke Cornelia, Marschner Norbert, Möbus Volker, Scheithauer Heike, Schneeweiss Andreas, Untch Michael
Neurologische Aspekte bei HIV und Syphilis
Leupold D, Dollmaier G, Hundsberger T. Neurologische Aspekte bei HIV und Syphilis - Wie manifestieren sich die Infektionserkrankungen am Nervensystem. InFo Neurologie & Psychiatrie 2015; 13:2-7.
22.06.2015Neurologische Aspekte bei HIV und Syphilis
22.06.2015InFo Neurologie & Psychiatrie 2015; 13:2-7
Leupold Daniela, Dollmaier Günter, Hundsberger Thomas
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
Schramm A, De Gregorio N, Widschwendter P, Fink V, Huober J. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel) 2015; 10:173-8.
18.06.2015Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
18.06.2015Breast Care (Basel) 2015; 10:173-8
Schramm Amelie, De Gregorio Nikolaus, Widschwendter Peter, Fink Visnja, Huober Jens
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75:556-565.
17.06.2015Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
17.06.2015Geburtshilfe Frauenheilkd 2015; 75:556-565
Untch M, Blohmer J-U, Costa S-D, Decker T, Diel I, Fasching P A, Fehm T, Janni W, Lück H-J, Maass N, Scharl A, Beckmann M W, Jackisch C, Thomssen C, Harbeck N, Huober Jens, von Minckwitz G, Gerber B, Kreipe H-H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S
[Osteosarcomas: very rare but curable with your help]
Cerny T. [Osteosarcomas: very rare but curable with your help]. Praxis (Bern 1994) 2015; 104:657.
17.06.2015[Osteosarcomas: very rare but curable with your help]
17.06.2015Praxis (Bern 1994) 2015; 104:657
Cerny Thomas
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
Vera-Badillo F, Tannock I, Bedard P, Goldstein R, Seruga B, Templeton A, Ocana A, Kuruzar G, Chang M, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. J Clin Pathol 2015
15.06.2015Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
15.06.2015J Clin Pathol 2015
Vera-Badillo Francisco E, Tannock Ian F, Bedard Philippe L, Goldstein Robyn, Seruga Bostjan, Templeton Arnoud, Ocana Alberto, Kuruzar Gordana, Chang Martin C, Amir Eitan
Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
Müller K, Hundsberger T, Kortmann R, Klautke G, Matuschek C, Friedrich C, Compter I, von Bueren A, De Vleeschouwer S, van Gool S, Pietschmann S, Henke G, Baumert B. Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model. J Neurooncol 2015; 124:325-32.
13.06.2015Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
13.06.2015J Neurooncol 2015; 124:325-32
Müller Klaus, Hundsberger Thomas, Kortmann Rolf-Dieter, Klautke Gunther, Matuschek Christiane, Friedrich Carsten, Compter Inge, von Bueren André O, De Vleeschouwer Steven, van Gool Stefaan, Pietschmann Sophie, Henke Guido, Baumert Brigitta G
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
11.06.2015The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
11.06.2015Haematologica 2015; 100:1350-60
Kraus Marianne, Overkleeft Herman, Kisselev Alexei F, Li Nan, Appenzeller Christina, van Rooden Eva, Haile Sarah, de Bruin Gerjan, van der Linden Wouter A, Shabaneh Tamer B, Silzle Tobias, Mirabella Anne C, Weyburne Emily S, Geurink Paul P, Bader Juergen, Driessen Christoph
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26:1589-604.
03.06.2015Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
03.06.2015Ann Oncol 2015; 26:1589-604
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke